Molecular Partners AG (0QXX) Stock Statistics & Valuation Metrics
Total Valuation
Molecular Partners AG has a market cap or net worth of CHF 116.68M. The enterprise value is CHF 55.01M.
- Market Cap
- CHF 116.68M
- Enterprise Value
- CHF 55.01M
Share Statistics
Molecular Partners AG has 40,374,640 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 40,374,640
- Owned by Insiders
- ―
- Owned by Institutions
- 0.03%
Financial Efficiency
Molecular Partners AG’s return on equity (ROE) is -0.77 and return on invested capital (ROIC) is -60.07%.
- Return on Equity (ROE)
- -0.77
- Return on Assets (ROA)
- -0.60
- Return on Invested Capital (ROIC)
- -60.07%
- Return on Capital Employed (ROCE)
- -0.61
- Revenue Per Employee
- 0
- Profits Per Employee
- -460.08K
- Employee Count
- 134
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Molecular Partners AG is -2.14. Molecular Partners AG’s PEG ratio is -0.12.
- PE Ratio
- -2.14
- PS Ratio
- 0.00
- PB Ratio
- 2.19
- Price to FCF
- -2.40
- Price to Operating Cash Flow
- -2.41
- PEG Ratio
- -0.12
Income Statement
In the last 12 months, Molecular Partners AG had revenue of 0 and earned -61.65M in profits. Earnings per share was -1.65.
- Revenue
- 0
- Gross Profit
- -2.15M
- Operating Income
- -55.44M
- Pretax Income
- -61.65M
- Net Income
- -61.65M
- EBITDA
- -53.29M
- Earnings Per Share (EPS)
- -1.65
Cash Flow
In the last 12 months, operating cash flow was -46.04M and capital expenditures -159,000, giving a free cash flow of -46.20M billion.
- Operating Cash Flow
- -46.04M
- Free Cash Flow
- -46.20M
- Free Cash Flow per Share
- -1.21
Dividends & Yields
Molecular Partners AG pays an annual dividend of CHF 0.29, resulting in a dividend yield of ―
- Dividend Per Share
- CHF 0.29
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -41.73%
- Earnings Yield
- -46.14%
Stock Price Statistics
- Beta
- 0.96
- 52-Week Price Change
- 3.44%
- 50-Day Moving Average
- 3.31
- 200-Day Moving Average
- 3.31
- Relative Strength Index (RSI)
- 36.78
- Average Volume (3m)
- 1,172
Important Dates
Molecular Partners AG upcoming earnings date is Mar 05, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 25, 2026
- Next Earnings Date
- Mar 05, 2027
- Ex-Dividend Date
- Mar 15, 2022
Financial Position
Molecular Partners AG as a current ratio of 8.79, with Debt / Equity ratio of 4.54%
- Current Ratio
- 8.79
- Quick Ratio
- 8.79
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.48
- Interest Coverage Ratio
- -15.84
Taxes
In the past 12 months, Molecular Partners AG has paid 2,000 in taxes.
- Income Tax
- 2,000
- Effective Tax Rate
- -0.00
Enterprise Valuation
Molecular Partners AG EV to EBITDA ratio is -1.14, with an EV/FCF ratio of -1.21.
- EV to Sales
- 0.00
- EV to EBITDA
- -1.14
- EV to Free Cash Flow
- -1.21
- EV to Operating Cash Flow
- -1.22
Balance Sheet
Molecular Partners AG has CHF 57.49M in cash and marketable securities with CHF 2.74M in debt, giving a net cash position of CHF 54.75M billion.
- Cash & Marketable Securities
- CHF 57.49M
- Total Debt
- CHF 2.74M
- Net Cash
- CHF 54.75M
- Net Cash Per Share
- CHF 1.36
- Tangible Book Value Per Share
- CHF 1.32
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Molecular Partners AG is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -100.00%
- EPS Growth Forecast
- 24.46%